Brain-Soultherapy s.r.o.

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• Depression6 trials
• Alzheimer disease4 trials
• Migraine2 trials
• Insomnia1 trial

Phase

• Phase 37 trials
• Phase 2/33 trials
• Phase 22 trials

Status

• Completed8 trials
• Recruiting2 trials
• Active, not recruiting1 trial
• Suspended1 trial

Lead sponsor

• AbbVie2 trials
• ACADIA Pharmaceuticals Inc.2 trials
• Exciva GmbH1 trial
• Green Valley (Shanghai) Pharmaceuticals Co., Ltd.1 trial
• Janssen Cilag International1 trial
• and 5 more

Running trials

• Recruiting

  Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia

  NCT07284472· Phase 2/3· Exciva GmbH· Source

• Active, not recruiting

  A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine

  NCT06602479· Phase 2· AbbVie· Source

• Enrolling by invitation

  ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study

  NCT06194799· Phase 3· ACADIA Pharmaceuticals Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease2 recruiting

Closed trials

• Completed

  A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and an Open- labeled Long-term Extension Treatment with Aticaprant

  2024-511557-21-00· Phase 3· Janssen Cilag International· Source

• Completed

  Long-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants with Major Depressive Disorder

  NCT06029439· Phase 3· Neumora Therapeutics Inc.· Source

• Completed

  Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder

  NCT06058039· Phase 3· Neumora Therapeutics, Inc.· Source

• Recruiting

  ACP-204 in Adults With Alzheimer's Disease Psychosis

  NCT06159673· Phase 2/3· ACADIA Pharmaceuticals Inc.· Source

• Completed

  Protocol Lay Person Short Title: A Trial of the Safety and Efficacy of Flexible Doses of SEP-363856 as Adjunctive Therapy in the Treatment of Adults with Major Depressive Disorder.

  2022-500538-27-00· Phase 2/3· Otsuka Pharmaceutical Development And Commercialization Inc.· Source

• Completed

  A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder

  NCT05593029· Phase 2· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

• Completed

  A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine

  NCT04686136· Phase 3· AbbVie· Source

• Completed

  A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant

  NCT04533529· Phase 3· Janssen Research & Development, LLC· Source